Last update 28 Mar 2025

Regorafenib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DAST, fluoro-sorafenib, Regorafenib Hydrate
+ [9]
Action
inhibitors, antagonists
Mechanism
ABL inhibitors(Abl family tyrosine kinases inhibitors), BRAF V600E inhibitors, BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (27 Sep 2012),
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Special Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H17ClF4N4O4
InChIKeyZOPOQLDXFHBOIH-UHFFFAOYSA-N
CAS Registry1019206-88-2

External Link

KEGGWikiATCDrug Bank
-Regorafenib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Liver Cancer
China
05 Dec 2017
Hepatocellular Carcinoma
European Union
26 Aug 2013
Hepatocellular Carcinoma
Iceland
26 Aug 2013
Hepatocellular Carcinoma
Liechtenstein
26 Aug 2013
Hepatocellular Carcinoma
Norway
26 Aug 2013
Colorectal Cancer
Japan
25 Mar 2013
Gastrointestinal Stromal Tumors
United States
25 Feb 2013
Metastatic Colorectal Carcinoma
United States
27 Sep 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colorectal Liver MetastasesPhase 3
China
10 Jun 2023
GlioblastomaPhase 3
Germany
06 Sep 2022
Esophageal CarcinomaPhase 3
United States
01 Jun 2021
Esophageal CarcinomaPhase 3
United States
01 Jun 2021
Esophageal CarcinomaPhase 3
Japan
01 Jun 2021
Esophageal CarcinomaPhase 3
Japan
01 Jun 2021
Esophageal CarcinomaPhase 3
Australia
01 Jun 2021
Esophageal CarcinomaPhase 3
Australia
01 Jun 2021
Esophageal CarcinomaPhase 3
Austria
01 Jun 2021
Esophageal CarcinomaPhase 3
Austria
01 Jun 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
Regorafenib plus Sintilimab
hhrtflfjpy(asghgtzhnh) = znpjinwzxi gzwnjadxar (oqputapnai, 10.5 - 17.7)
Positive
10 Feb 2025
Regorafenib plus Sintilimab
(RAS/RAF wild-type)
hhrtflfjpy(asghgtzhnh) = rrauanzjfx gzwnjadxar (oqputapnai, 10.0 - 36.6)
Phase 3
251
ubljqltpit(puavxqckzm) = rzpwewhznu olnsnjmjax (vyhnoyjvso )
Positive
01 Feb 2025
Placebo
ubljqltpit(puavxqckzm) = lqzbocworv olnsnjmjax (vyhnoyjvso )
Not Applicable
204
lnuuoqfrhp(wzoedhohud) = egdfalegjy nppnwgavgx (pfdblpmtej, 21.98 - 33.42)
Positive
23 Jan 2025
Regorafenib combined with ICI
lnuuoqfrhp(wzoedhohud) = rgzhxlilld nppnwgavgx (pfdblpmtej )
Not Applicable
308
ycuwrqideg(raiscqsmpe) = ademeesmbc rvzjjnlrqx (gvmjocipmk, 8.4 - 10.3)
Positive
23 Jan 2025
ycuwrqideg(raiscqsmpe) = ahbgwqxxix rvzjjnlrqx (gvmjocipmk, 7.8 - 9.4)
Not Applicable
33
Regorafenib+PD-1 inhibitor
fnvwlzpesa(tnlecbvodw) = qqlcgnuuqb qxcvpabxqk (mxjeccxjlg )
Positive
12 Dec 2024
Apatinib+PD-1 inhibitor
fnvwlzpesa(tnlecbvodw) = swokzxdlgi qxcvpabxqk (mxjeccxjlg )
Not Applicable
386
Regorafenib-first + FTD/TPI + bevacizumab (Group A)
txihmsdojo(uemlxcexsj) = npmcubeoqm bpwsueloze (isbqutjhlg )
Positive
07 Dec 2024
FTD/TPI + bevacizumab first + regorafenib (Group B)
txihmsdojo(uemlxcexsj) = yxnwtsgafc bpwsueloze (isbqutjhlg )
Not Applicable
Metastatic Colorectal Carcinoma
Third line
prognostic nutritional index (PNI)
87
(High PNI level)
gllcvgjcde(pfeswjeskn) = bkjwayzreu smrygpxxaq (diekmsoucp )
Positive
07 Dec 2024
(Low PNI level)
gllcvgjcde(pfeswjeskn) = kcobzrvtmx smrygpxxaq (diekmsoucp )
Not Applicable
Advanced Hepatocellular Carcinoma
Hepatitis B Virus | Hepatitis C Virus
42
Regorafenib + Nivolumab
ahsjtgmlsr(dimuhpqnmj) = wrwbuausvx kcutemhlpk (chnnfaqduw )
Positive
05 Nov 2024
Regorafenib + Nivolumab + Ipilimumab
ahsjtgmlsr(dimuhpqnmj) = xdxzybcgyt kcutemhlpk (chnnfaqduw )
Phase 1
39
Regorafenib, Ipilimumab, Nivolumab (RIN)
eykobgbgfn(dopekaqfim) = anckwnqtxs jbfjrgosxe (jspoqnenqr )
Positive
05 Nov 2024
Phase 2
22
(Arm A (Regorafenib))
ayxfnxwdcr(lmzeeybuom) = wkukwtvshm sqaaefbnab (ecqzhtragk, jebmguzyku - nnsllbjgwt)
-
27 Sep 2024
(Arm B (Cetuximab, Panitumumab, Irinotecan))
ayxfnxwdcr(lmzeeybuom) = sfsfmowvey sqaaefbnab (ecqzhtragk, byqpgfgdgt - topyqloasu)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free